By Erfan Akbraian, Analyst Email: eakbraian@partners4access.com In recent years there have been discussions to shift to a multi-stakeholder approach and increase early communication amongst key stakeholders to ensure appropriate access of advanced therapy medicinal products (ATMPs). With an increasing number of ATMPs for orphan diseases in the pipeline, there is a need for health technology…
Leading specialist market access consultancy Partners4Access (P4A) is to host a free webinar to share insights on key 2021 trends in market access for pharma/biotech manufacturers. The webinar titled ` EU Market Access 2021:What’s in store for Orphan Drugs and ATMPs?’ will be conducted by educational webinars provider Xtalks and will be held on Wednesday,…
2019 set the tone for innovative therapies in the cell and gene therapy space along with huge interest from Big Biotech. With an expected double digit growth trajectory in the orphan drug market, 2020 is going to be a busy year. Here are the top trends from P4A’s experts to help you navigate the year…